Imeglimin (EMD- 387008,PXL- 008,RVT-1501, brand name Twymeeg) is an oral anti-diabetic medication.

[1][2] It was approved for use in Japan in June 2021.

[3] It is an oxidative phosphorylation blocker that acts to inhibit hepatic gluconeogenesis, increase muscle glucose uptake, and restore normal insulin secretion.

It is the first approved drug of this class of anti-diabetic medication.

This drug article relating to the gastrointestinal system is a stub.